Welcome to our dedicated page for Inmed Pharmaceuticals news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on Inmed Pharmaceuticals stock.
Company Overview
InMed Pharmaceuticals Inc (INM) is a Canada-based, clinical-stage biopharmaceutical company dedicated to developing novel, proprietary small molecule drug candidates. Leveraging extensive expertise in cannabinoid pharmacology and innovative drug delivery systems, InMed focuses on addressing high unmet medical needs across neurodegenerative, ocular, and dermatological indications. The company operates at the intersection of advanced biotechnology and pharmaceutical innovation, integrating targeted research with a robust patent portfolio to protect its unique therapeutic approaches.
Core Business Areas
At its core, InMed is engaged in the research, development, and manufacturing of pharmaceutical-grade cannabinoids and small molecule analogs. Its pipeline includes candidates designed for the treatment of complex conditions such as Alzheimer’s disease, dry age-related macular degeneration, and epidermolysis bullosa. By emphasizing a multi-faceted approach to drug development, InMed not only explores the therapeutic potential of cannabinoid-based compounds, but also ensures the advancement of its clinical stage programs through meticulous preclinical studies and strategic partnerships.
Technology and Proprietary Platform
The company’s proprietary platform is central to its operations. This platform combines the extensive pharmacology of cannabinoids with innovative drug delivery systems to optimize therapeutic efficacy. InMed’s approach enables oral bioavailability and effective delivery of its drug candidates to target tissues, thus addressing challenges associated with existing treatment modalities. This technological edge is underpinned by a strong intellectual property portfolio, including multiple patent families that encompass novel compositions, formulations, manufacturing processes, and methods of use.
Research and Development Focus
Research and development are pivotal to the company’s value proposition. InMed’s rigorous preclinical studies test the efficacy of candidates such as INM-901, designed to modulate neuroinflammation and improve neuronal function, as well as INM-089, intended for ocular indications like dry age-related macular degeneration. These drug candidates are characterized by their multi-mechanistic actions, often targeting the CB1/CB2 receptors to address complex disease pathways. The company’s scientific efforts are supported by continuous advancements in chemistry, manufacturing, and controls (CMC) to ensure a seamless transition from preclinical studies to clinical trials.
Market Position and Competitive Landscape
InMed occupies a distinctive position within the biopharmaceutical space. Its focus on the specialized niche of cannabinoid-based therapies for diseases with high unmet needs distinguishes it from broader pharmaceutical companies. The company’s competitive advantage stems from its comprehensive integrated approach—melding innovative research, a rigorously maintained patent portfolio, and cutting-edge drug delivery formulations. This positions InMed as a knowledgeable and specialized player in its industry, capable of addressing complex therapeutic challenges through targeted small molecule candidates.
Value Proposition and Industry Impact
Through its advanced technology and sustained commitment to R&D, InMed Pharmaceuticals Inc delivers significant value by exploring new modalities in the treatment of debilitating diseases. The company’s exploration into multiple disease areas using its proprietary cannabinoid platform demonstrates its expertise and long-standing dedication to innovation. InMed’s work contributes to a deeper understanding of disease mechanisms, offering an informed perspective on how alternative therapeutic approaches can redefine the landscape in areas traditionally dominated by conventional treatments.
InMed Pharmaceuticals Inc. announces the voluntary delisting of its common shares from the Toronto Stock Exchange (TSX) while maintaining its listing on the Nasdaq. This decision comes as trading volume on the TSX no longer justifies the costs associated with dual listing. InMed’s shares have primarily traded on Nasdaq, accounting for approximately 86% of trading volume since November 2020. The anticipated delisting from the TSX will occur around May 7, 2021, with Canadian shareholders able to trade their shares on Nasdaq through their brokers.
InMed Pharmaceuticals has achieved a cannabinoid yield of 2g/L via its IntegraSyn™ manufacturing approach, marking a significant milestone towards commercial viability. The company aims to scale up production for pharmaceutical-grade cannabinoids and optimize manufacturing costs. InMed plans to produce a one-kilogram batch in the second half of 2021. They are also preparing for Good Manufacturing Practice (GMP) certification. This achievement positions InMed for potential advancements in cannabinoid-based pharmaceutical drugs.
InMed Pharmaceuticals has announced participation in two investor conferences in March 2021. Eric A. Adams, President and CEO, will present at the H.C. Wainwright Global Life Sciences Conference from March 9-10, with an on-demand presentation available starting March 9 at 7 AM EST. Additionally, he will engage in a Fireside Chat at the 33rd Annual ROTH Conference on March 15 at 4:30 PM EST. InMed is focused on developing cannabinoid-based pharmaceutical candidates, specifically targeting unmet medical needs through cannabinol (CBN).
InMed Pharmaceuticals has completed a private placement, raising approximately US$4.0 million in net proceeds by selling 1,050,000 units at US$4.25 per unit. Each unit consists of one common share and 0.66 of a warrant with an exercise price of US$4.85.
The funds will be used for working capital purposes. InMed plans to file a registration statement with the SEC within 30 days for the common shares and warrants issued, although these securities have not been registered under the Securities Act.
InMed Pharmaceuticals, a clinical-stage pharmaceutical company, has successfully closed a private placement raising approximately US$4.0 million. A total of 1,050,000 units were sold at US$4.25 per unit, each unit comprising one common share and 0.66 of a warrant. The warrants have an exercise price of US$4.85 and are exercisable six months post-issuance. InMed will use the proceeds for working capital. The securities issued will not be registered under the Securities Act, and InMed is set to file a registration statement with the SEC within 30 days.
InMed Pharmaceuticals reported its fiscal Q2 2021 financial results, highlighting a net loss of $2.2 million, down from $2.5 million a year ago. The company achieved significant milestones for its INM-755 program, targeting Epidermolysis Bullosa, demonstrating safety and tolerability in Phase 1 trials. Cash reserves improved to $10.1 million, up from $4.5 million in September 2020, following an $8 million public offering. InMed also entered a licensing agreement for ocular drug delivery technology aimed at glaucoma treatment.
InMed Pharmaceuticals reported its second quarter fiscal 2021 financial results, ending December 31, 2020. The company achieved critical milestones in its drug development, particularly for INM-755 aimed at Epidermolysis Bullosa, with upcoming Phase 2 trials planned. It secured a worldwide license for ocular drug delivery technology, MiDROPS®, enhancing its research pipeline. Financially, InMed raised about $12.5 million through recent offerings and recorded a net loss of $2.2 million in Q2 2021, an improvement from $2.5 million in Q2 2020.
InMed Pharmaceuticals Inc. (NASDAQ: INM) will report its financial results for the second quarter of fiscal year 2021, ending December 31, 2020, on February 11, 2021. A conference call and webcast will occur at 8:30 AM Pacific Time. The company is focused on developing cannabinoid-based medications, particularly targeting the therapeutic benefits of cannabinol (CBN). Full financial statements will be accessible on their website and regulatory authorities after the announcement.
InMed Pharmaceuticals Inc. (NASDAQ: INM), a clinical-stage pharmaceutical company, is set to report its financial results for Q2 of fiscal year 2021 on February 11, 2021. The company focuses on developing cannabinoid-based medications, specifically cannabinol (CBN) for diseases with high unmet medical needs. A conference call and webcast will take place on the same day at 8:30 AM PT with details available on their website. InMed emphasizes its commitment to delivering therapeutic alternatives while navigating the uncertainties inherent in clinical development.
InMed Pharmaceuticals Inc. announced a private placement to raise approximately US$4.5 million, issuing units at US$4.25 per share. Each unit consists of one common share and 0.66 warrants with an exercise price of US$4.85. The expected net proceeds are about US$4.0 million, intended for working capital. The offering is expected to close around February 12, 2021, pending regulatory approval. Roth Capital Partners is the placement agent, and InMed will file a registration statement for resales within 30 days post-closing.
FAQ
What is the current stock price of Inmed Pharmaceuticals (INM)?
What is the market cap of Inmed Pharmaceuticals (INM)?
What does InMed Pharmaceuticals Inc specialize in?
How does the company generate its revenue?
What are the core therapeutic areas of InMed?
How does InMed protect its innovations?
How is InMed different from other biopharmaceutical companies?
What key product candidates are under development?
